Cellectar Biosciences Inc (CLRB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cellectar Biosciences Inc stock (CLRB) is currently trading at $3.01. Cellectar Biosciences Inc PS ratio (Price-to-Sales) is 348.47. Analyst consensus price target for CLRB is $33.33. WallStSmart rates CLRB as Sell.
- CLRB PE ratio analysis and historical PE chart
- CLRB PS ratio (Price-to-Sales) history and trend
- CLRB intrinsic value — DCF, Graham Number, EPV models
- CLRB stock price prediction 2025 2026 2027 2028 2029 2030
- CLRB fair value vs current price
- CLRB insider transactions and insider buying
- Is CLRB undervalued or overvalued?
- Cellectar Biosciences Inc financial analysis — revenue, earnings, cash flow
- CLRB Piotroski F-Score and Altman Z-Score
- CLRB analyst price target and Smart Rating
Cellectar Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Cellectar Biosciences Inc (CLRB) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Cellectar Biosciences Inc (CLRB) Key Strengths (1)
Trading at 1.70x book value, attractively priced
Supporting Valuation Data
Cellectar Biosciences Inc (CLRB) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 348.5x annual revenue
Very low institutional interest at 8.28%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Cellectar Biosciences Inc (CLRB) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 8.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.70) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (348.47) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -170.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -170.30% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CLRB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CLRB's Price-to-Sales ratio of 348.47x trades 66% above its historical average of 210.18x (82th percentile), historically expensive. The current valuation is 58% below its historical high of 822.99x set in Jul 2014, and 19699% above its historical low of 1.76x in Nov 2010.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cellectar Biosciences Inc (CLRB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cellectar Biosciences Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cellectar Biosciences Inc.
Bottom Line
Cellectar Biosciences Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cellectar Biosciences Inc(CLRB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development and commercialization of drugs for the treatment of cancer. The company is headquartered in Florham Park, New Jersey.